Background. The incidence of venous thromboembolism (VTE) after lung transplantation (LTX) varies significantly across studies. Two studies have suggested that these thrombotic events are associated with a lower posttransplant survival. Herein, we sought to determine the incidence, predictors, and impact of VTE on survival after LTX at a quaternary referral center. Methods. This was a large cohort study of LTX recipients. Key outcome parameters were time to VTE after transplant and survival. Deep vein thrombosis (DVT) diagnosis required a positive ultrasound. Pulmonary embolism diagnosis required either a positive chest computed tomography angiogram or a high-probability ventilation/perfusion scan. Results. The overall incidence of VTE among 701 LTX recipients was 43.8%, of which 97.7% were DVT episodes, of which 71.3% were in the upper extremities. Predictors of VTE were prior history of DVT (hazard ratio [HR], 2.82; 95% confidence interval [CI], 1.49-5.37), days in intensive care (HR, 1.01; 95% CI, 1.01-1.02), and the use of extracorporeal membrane oxygenation (HR, 2.22; 95% CI, 1.43-3.45). Importantly, VTE predicted a lower posttransplant survival (HR, 1.70; 95% CI, 1.28-2.26), when occurring within or after the first 30 days. The location of the DVT, either upper extremity or below the knee, also predicted a poor survival. Conclusions. VTE was frequent in LTX recipients and predicted a poor survival even when located in the upper extremities or below the knee. These data suggest that aggressive VTE screening/treatment protocols be implemented in post-LTX population.
T hree decades have passed since the first successful lung transplantation (LTX) in 1983. 1 Thereafter, LTX has evolved to represent the therapy of choice for a growing number of patients with end-stage lung diseases. In selected patients, LTX may significantly prolong survival and improve quality of life. 2 Despite its many benefits, LTX recipients face many challenges including drug toxicity, infections and rejection. 3 Venous thromboembolism (VTE) has been reported to be one of these challenges.
Studies to date demonstrate a widely varied incidence of VTE in this population (9-64%). [4] [5] [6] [7] [8] [9] [10] Most VTE episodes after LTX are a consequence of deep vein thromboses (DVT), [4] [5] [6] [7] 9, 10 with the predominant location being upper or lower extremity depending on the study. 4, 6, 9 Among lower-extremity DVTs (LEDVT), no study has discriminated proximal (above the knee) from distal (below the knee) LEDVT. The incidence of pulmonary embolism (PE) also varies widely (1.7-15.3%). [4] [5] [6] [7] [9] [10] [11] [12] Previously identified risk factors for VTE after LTX include hypercoagulable states, 5 older age, diabetes mellitus, pneumonia, 6 cardiopulmonary bypass (CPB), 7 and sirolimus therapy when administered post-LTX. 8, 9 Furthermore, studies have suggested that the presence of central venous catheters (CVC) is a risk factor for upper-extremity DVT (UEDVT). 4, 6, 7 However, the association of VTE with the underlying lung disease leading to transplant is less well substantiated. As epidemiological studies link idiopathic pulmonary fibrosis (IPF) to VTE episodes, [13] [14] [15] and animal studies demonstrate amelioration of pulmonary fibrosis upon manipulation of the coagulation cascade, [16] [17] [18] it has been suggested that patients with IPF are at increased risk of developing VTE post-LTX. 11, 12 There remains equipoise in the literature regarding the risk of VTE after LTX for IPF. 7 Smaller studies suggest that VTE after LTX is associated with a worse survival. 8, 10 Herein, we investigated the incidence and location of VTE after LTX, as well as its risk factors and impact on survival in a large cohort of LTX patients from 1 worldwide quaternary referral center.
MATERIAL AND METHODS

Protection of Human Subjects
The study protocol was approved by the institutional review board of the Cleveland Clinic, Cleveland, Ohio (IRB 12-763). A waiver of consent was granted due to the acknowledged minimal risk to the patients.
Design and Population
This was a retrospective analysis of the database comprised of all patients who underwent LTX at the Cleveland Clinic from January 2005 until October 10, 2012. In this cohort study, the starting point was the exposure (eg, underlying lung disease, type of surgical procedure), then the groups were followed forward in time to determine numbers of disease (VTE) events in exposed and unexposed subjects. The starting date was chosen based on the completeness of our database. However, direct review of the electronic medical records was performed when necessary. Combined heart-lung, liver-lung transplants, and lung retransplant patients were excluded. The DVT testing results were obtained from a separate database.
Definitions and Outcomes
Our primary outcome variable was time to the first episode of VTE post-LTX. DVT was defined as a positive duplex ultrasound of any of the extremities. We further characterized the DVTs as UEDVT, LEDVT above the knee, and LEDVT below the knee. PE was defined as a positive chest computed tomography angiogram, or a high-probability ventilation/ perfusion scan. VTE episodes were stratified into early (within 30 days) and late (after 30 days) according to the time posttransplant. Diagnostic studies were performed based on clinical decision during post-LTX care. A DVT screening protocol designed to enhance duplex ultrasound screening on days 1 and 3 postoperative was implemented in 2010.
Predictors
Our main independent variable was the underlying lung disease. Our secondary independent variables were: age, sex, prior history of DVT, Lung Allocation Score (LAS), cumulative intensive care unit (ICU) days, type of surgical procedure (single, bilateral sequential, or en bloc LTX), use of perioperative extracorporeal membrane oxygenation (ECMO), use of intraoperative CPB, and presence of cancer posttransplant.
Statistical Analysis
The continuous variables were described using median with interquartile range, and the categorical variables were summarized using absolute and relative frequencies. The study group was stratified by VTE status post-LTX, as well as by early (≤30 days) or late (>30 days) VTE. Continuous variables were compared using the Mann-Whitney U test or Kruskal-Wallis test, and categorical variables were compared using the Pearson χ 2 test or Fisher exact test as appropriate. Post hoc tests used were Games-Howell and Bonferroni approaches for multiple comparisons. Time to VTE was analyzed in 2 different ways: (1) using the mean and median time to VTE, (2) using the Kaplan-Meier method. The Kaplan-Meier data were summarized in cumulative survival graphs, and survival curves were compared using the logrank test. Logistic and Cox regression analyses were conducted to identify potential predictors of outcomes. Variables with a P value less than 0.20 on univariate analyses were included in multivariate models. Stepwise variable selection procedure was then performed to select a significant subset of predictors. A P value less than 0.05 on multivariate analysis was considered statistically significant. Statistical analyses were conducted using the IBM SPSS Statistics version 21.0 software package.
RESULTS
Study Population
We screened 730 patients who underwent LTX from January 2005 until October 10, 2012. We excluded 20 heart-lung, 4 liverlung transplant patients, and 5 lung retransplant patients. Our final sample comprised 701 LTX recipients. Median time of follow-up was 1.8 years (range, 0-7.5 yrs). Demographics and clinical characteristics of the sample are shown in Table 1 .
Incidence, Location, and Timing of VTE
We performed duplex ultrasound of the extremities in a high proportion of our patients (79.9%) during the whole study period. We detected a high incidence of VTE during the follow-up period (43.8% of patients), mainly driven by episodes of DVT (42.8% of patients) (see Table 2 ). The majority of DVTs originated in the upper extremities (71.3% of DVT episodes). The majority of LEDVTs originated below the knee (58.1% of LEDVT episodes). The incidence of PE was much lower (4.7% of LTX patients).
In those with VTE, the median time to VTE was 20 days (p25-p75, 9-82 days), whereas the mean time to VTE was 132 days (95% CI, 100-164 days). Most VTE episodes (63.8%) happened in the first month posttransplant. The time for half of the patients to develop VTE was approximately 3 years (Kaplan-Meier analysis).
From 2005 to 2009, 5.5% (22/399) had ultrasounds, whereas between 2010 and 2012, 45.4% (137/302; P < 0.001) had ultrasounds within the first 3 days after transplantation. Upon implementation of screening protocol in 2010, VTE rates within the first 3 days after transplantation tripled (2.0% to 6.6%; P = 0.002).
Risk Factors for VTE
To identify the variables associated with time to VTE post-LTX, we performed univariate and multivariate Cox regression analyses (Table 3) . Univariate time to VTE analysis revealed that prior history of DVT, LAS, cumulative ICU days, and use of ECMO were associated with VTE. Prior history of DVT (HR, 2.82; 95% CI, 1.49-5.37; P = 0.002), cumulative ICU days (HR, 1.01; 95% CI, 1.01-1.02; P < 0.001), and the use of ECMO (HR, 2.22; 95% CI, 1.43-3.45; P < 0.001) remained associated with time to VTE upon Cox regression multivariate analysis (Table 3) . Importantly, we saw no association of underlying disease or of LTX procedure with post-LT VTE.
Characteristics of Early Versus Late VTE
We suspected that early VTE was a consequence of different underlying risks compared with late VTE. To further explore potential underlying risks of VTE at different time point post-LTX, we directly compared the clinical characteristics of patients with VTE that occurred early (within 30 days) or late (after 30 days) after LTX by univariate analysis (Table 4) . This univariate analysis revealed that male sex, the use of ECMO, longer ICU stay and UEDVT were more common in the early VTE group (P < 0.05). Upon multivariate Cox regression analyses, male sex (HR, 1.40; 95% CI, 1.03-1.9; P = 0.032) and the use of ECMO (HR, 1.77; 95% CI, 1.15-2.71; P = 0.009) were independently associated with early VTE.
Risk Factors for Specific VTE Anatomical Locations
Because the most common VTE location in our study was in the upper extremities (UEDVT), we performed univariate and multivariate logistic regression analyses to identify independent risk factors for this outcome. The only variables independently associated with UEDVT were age (OR, 0.98; 95% CI, 0.97-0.99; P = 0.045) and cumulative ICU days (OR, 1.03; 95% CI, 1.01-1.04; P < 0.001). The introduction of underlying diagnosis did not affect the model significantly. No variables were associated with PE, neither in the univariate analysis nor in the final multivariate analysis model.
VTE and Survival
To study the association between VTE and survival after LTX, we first performed a univariate survival analysis of time to death posttransplant. The median survival time was 5.0 years (95% CI, 3.90-6.04). The presence of VTE was associated with worse survival (Figure 1 , P < 0.001). We found that VTE remained independently associated with a lower survival upon multivariate Cox regression analysis after adjustment for age, underlying diagnosis, type of surgical procedure, use of ECMO, presence of cancer posttransplant, and cumulative ICU days, (HR, 1.70; 95% CI, 1.28-2.26; P < 0.001; Table 5 ). When stratifying VTE by timing of occurrence (≤30 or >30 days after LTX), both early and late VTEs were individually associated with worse survival (P < 0.001) (Figure 2 ) in univariate survival analysis. These significant associations were maintained in multivariate Cox regression analysis (early: HR, 1.52; 95% CI, 1.09-2.11; P = 0.013; late: HR, 1.95; 95% CI, 1.39-2.73; P < 0.001). We had 143 patients who had a VTE and died during the follow-up period. Among those with early VTE (≤30 days), the time between VTE and death ranged from 3 to 2730 days (median, 325 days) with 14.5% dying within 2 weeks of VTE diagnosis. Among those with late VTE (>30 days), the time between VTE and death ranged from 0 to 1904 days (median, 137.5 days) with 18.3% dying within 2 weeks of VTE diagnosis.
When stratifying VTE by anatomical location (UEDVT, LEDVT above the knee, LEDVT below the knee and PE), all locations except LEDVT above the knee were individually associated with worse survival (P < 0.001) (Figure 3 ) in univariate survival analysis. These significant associations were maintained in multivariate Cox regression analysis (UEDVT: HR, 1.81; 95% CI, 1.32-2.48; P < 0.001; LEDVT below the knee: HR, 1.95; 95% CI, 1.14-3.32; P = 0.014; PE: HR, 1.87; 95% CI, 1.14-3.07; P = 0.013).
Two-hundred thirty patients (32.8% of study sample) died during the follow-up period. The causes of death were: infection (33.9%), rejection (12.6%), cardiovascular (9.1%), malignancy (6.5%), VTE (1.7%), and other causes (36.1%). There was no significant association between the presence of VTE and specific causes of death (P = 0.164).
DISCUSSION
To the best of our knowledge, this is the largest cohort study to date evaluating the incidence of VTE post-LTX, and its effect on survival. Unexpectedly, we found a high incidence of VTE (43.8%) during the follow-up period. Most of those VTEs occurred in the upper extremities and in the first postoperative month. VTE was associated with poor survival independent of the postoperative period. This survival effect was also documented when the VTE was located in the upper extremities or surprisingly, below the knee.
The VTE incidence in our study was higher than that described in many previous studies (9-21%). [4] [5] [6] [7] [8] [9] The most likely reason for the higher VTE incidence in our study (43.8%), as in Evans et al 10 (64%), is that our study collected data predominantly after the implementation of the LAS. The LAS is calculated from estimates of survival probability while on the LTX waiting list and after transplantation. 19 Since the implementation of the LAS, LTX recipients are more frequently placed on ECMO. 20, 21 We speculate that the increased incidence of VTE in our study might be partly explained by the increase in frequency of ECMO utilization, because ECMO was an independent VTE risk factor in our study. In addition, the LAS would prioritize those for LTX with more severely impaired physiology, some of which might contribute to increased VTE risk (eg, age, immobility). Another issue related to the high VTE incidence in our study compared with previous works is that UEDVT was not universally measured in previous studies. 5, 8 Lastly, all previous studies included only symptomatic VTEs. [4] [5] [6] [7] [8] [9] Our results of a tripling of VTE detection rates upon implementation of the early postoperative VTE screening protocol strongly support the development of VTE in asymptomatic patients. VTE also occurred earlier in our study (median, 20 days; p25-p75, 9-82 days) than in most previous work (range of median values, 47-285 days). [4] [5] [6] [7] [8] [9] However, our findings are similar to that described by Evans et al, 10 where the median time to UEDVT was 8 days, whereas the median time to LEDVT was 5.4 months. We speculate that ECMO use (because it was associated with early VTE) and the high incidence of UEDVT (2.5 more common than LEDVT) were contributing factors for the shorter median time to VTE in our study. This is the first study to describe the incidence of LEDVT below the knee, defined as DVT in the peroneal, posterior tibial, anterior tibial, gastrocnemius, and soleal veins [22] [23] [24] in the post-LTX population. The prognosis and management of this entity differs from proximal LEDVT, with current guidelines recommending serial ultrasound imaging over anticoagulation in patients with no symptoms, and in those with no risk factors for extension. 24 Indeed, the incidence of isolated LEDVT below the knee (7.1%) was higher than that for LEDVT above the knee (5.1%). Furthermore, the survival curve of LEDVT below the knee was statistically worse than the one for patients with no DVT, suggesting that LEDVT below the knee are not fully benign in this population. We did not have data on treatment or on serial ultrasound imaging of these DVT episodes, so we could not explore further the relevance of our findings.
In our data, ECMO therapy was associated with a 73.8% incidence of VTE and a shorter time to VTE posttransplant. ECMO has also been linked to VTE in critically ill children with cardiac disease (OR, 16; 95% CI, 7.5-37.7), 25 and in adults with respiratory failure (18.1% prevalence of VTE in ECMO patients). 26 Most patients in the latter study (92.3%) were asymptomatic and were diagnosed due to routine ultrasound after decannulation. In addition, a recent meta-analysis of 1763 patients from 12 studies found a VTE prevalence of 10% (95% CI 5 -15%) 27 in those who received ECMO. 27 Two independent studies noted a higher incidence in those which used a bicaval dual-lumen cannula. 26, 28 As our data suggest that LTX recipients have a higher ECMO-related thrombosis risk than other patient populations undergoing ECMO, further study is warranted to identify more efficacious strategies for VTE prophylaxis in this population.
Although small retrospective studies have suggested that LTX for IPF was linked to increased risk of PE posttransplant, 11, 12 our much larger study found that the underlying diagnosis leading to LTX was not associated with VTE (DVT or PE) posttransplant. This lack of association was observed in all univariate analyses, as well as when the variable was forced into the multivariable analyses. Our findings are concordant with other larger and well-designed studies, where the underlying diagnosis was also not associated with VTE posttransplant. 7, 10 Most importantly, we found that VTE was independently associated with mortality and time to death posttransplant. Our data add to that of smaller studies that suggest that VTE posttransplant is an independent predictor of mortality in this population. 8, 10 Compared with the The International Society for Heart & Lung Transplantation data from a similar period, 29 our overall median survival time was similar (5.0 vs 6.3 years) as were other predictors of survival in univariate analyses (ie, age, underlying diagnosis, type of procedure). However, VTE, either its incidence, or its predictive value for mortality, was not examined in the ISHLT report. Based on our high incidence of VTE in this population and its impact on survival, we would recommend to include VTE as a key variable in the next ISHLT report, and to consider routine screening of all post-LTX patients for DVT, especially in the early postoperative period and in those undergoing ECMO or with a prolonged ICU stay. Our study has some limitations. First and foremost, the retrospective nature of our study is inherently susceptible to bias, such as misclassification bias. Second, we did not have data on VTE prophylaxis or treatment strategies, which could impact the incidence and the prognosis of VTE, respectively. In addition, unique features of our posttransplant care could explain our findings, because they were derived from a single academic quaternary referral center. Data on the presence of CVC would have been of great value, because UEDVT was our most common subtype of VTE. As demonstrated in the study by Kahan et al, 7 the majority of UEDVT were CVC related, whereas the majority of LEDVT were not.
In conclusion, this large retrospective cohort study demonstrated that VTE was very frequent post-LTX, especially in the upper extremities, and in the first postoperative month. In addition, it refuted the argument that the underlying diagnosis, such as IPF, is a predictor of VTE posttransplant. Finally, it reinforced the hypothesis that episodes of VTE can independently predict mortality in LTX patients. Taken together, these data indicate an urgent need for the implementation of new and more comprehensive strategies to reduce the burden of VTE post-LTX.
